These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39093663)

  • 21. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.
    Catlett IM; Hu Y; Gao L; Banerjee S; Gordon K; Krueger JG
    J Allergy Clin Immunol; 2022 Jun; 149(6):2010-2020.e8. PubMed ID: 34767869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis.
    Galluzzo M; Vellucci L; Marcelli L; Paganini C; Bianchi L; Talamonti M
    Expert Opin Pharmacother; 2023 Jun; 24(9):981-988. PubMed ID: 37147879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021).
    Gonzalez Lopez de Turiso F; Guckian K
    Expert Opin Ther Pat; 2022 Apr; 32(4):365-379. PubMed ID: 35001782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.
    Martin G
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):417-435. PubMed ID: 36592300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold.
    Istanbullu H; Coban G; Turunc E; Disel C; Debelec Butuner B
    Bioorg Chem; 2024 Jul; 148():107430. PubMed ID: 38728909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
    Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
    J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.
    Tokarski JS; Zupa-Fernandez A; Tredup JA; Pike K; Chang C; Xie D; Cheng L; Pedicord D; Muckelbauer J; Johnson SR; Wu S; Edavettal SC; Hong Y; Witmer MR; Elkin LL; Blat Y; Pitts WJ; Weinstein DS; Burke JR
    J Biol Chem; 2015 Apr; 290(17):11061-74. PubMed ID: 25762719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TYK2 as a novel therapeutic target in psoriasis.
    Elyoussfi S; Rane SS; Eyre S; Warren RB
    Expert Rev Clin Pharmacol; 2023; 16(6):549-558. PubMed ID: 37287330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triple-action inhibitory mechanism of allosteric TYK2-specific inhibitors.
    Wang J; Batista VS; Bunick CG
    bioRxiv; 2023 Oct; ():. PubMed ID: 37873392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases.
    Mammoliti O; Martina S; Claes P; Coti G; Blanque R; Jagerschmidt C; Shoji K; Borgonovi M; De Vos S; Marsais F; Oste L; Quinton E; López-Ramos M; Amantini D; Brys R; Jimenez JM; Galien R; van der Plas S
    J Med Chem; 2024 Jun; 67(11):8545-8568. PubMed ID: 38805213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression patterns of three JAK-STAT pathway genes in feather follicle development during chicken embryogenesis.
    Tao Y; Zhou X; Liu Z; Zhang X; Nie Y; Zheng X; Li S; Hu X; Yang G; Zhao Q; Mou C
    Gene Expr Patterns; 2020 Jan; 35():119078. PubMed ID: 31759166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases.
    Chang Y; Xu S; Ding K
    J Med Chem; 2019 Oct; 62(20):8951-8952. PubMed ID: 31603320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.
    Kingston P; Blauvelt A; Strober B; Armstrong AW
    J Psoriasis Psoriatic Arthritis; 2023 Oct; 8(4):156-165. PubMed ID: 38188537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deucravacitinib: First Approval.
    Hoy SM
    Drugs; 2022 Nov; 82(17):1671-1679. PubMed ID: 36401743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis.
    Zheng Y; Han Y; Chen J; Huang J; Zhu C; Lin L; Su H
    Indian J Dermatol Venereol Leprol; 2024; 90(5):590-598. PubMed ID: 38899421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The preclinical discovery and development of deucravacitinib for the treatment of psoriasis.
    Coscarella G; Malvaso D; Mannino M; Caldarola G; Fossati B; De Simone C; Chiricozzi A; Peris K
    Expert Opin Drug Discov; 2023; 18(11):1201-1208. PubMed ID: 37574849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis.
    Xu Y; Li Z; Wu S; Guo L; Jiang X
    Front Immunol; 2023; 14():1180170. PubMed ID: 37334353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
    Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis.
    Gooderham MJ; Hong HC; Litvinov IV
    Skin Therapy Lett; 2022 Nov; 27(6):1-5. PubMed ID: 36469536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.